Get started
Author

Èric Massana

Observed names: E Massana, E. MASSANA, E. Massana, Eric Massana
Institution: Almirall (Spain)
OpenAlex ID: A5109829110
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
2021 · B.M. Piraccini, U. Blume‐Peytavi, et al. · Journal of the European Academy of Dermatology and Venereology · 199
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)
2023 · Matthias Augustin, Rachel Sommer, et al. · BMJ Open · 21
PDF
First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β2‐agonist
2014 · Wolfgang Timmer, Eric Massana, et al. · The Journal of Clinical Pharmacology · 20
Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
2016 · Jutta Beier, Helena Pujol, et al. · BMC Pulmonary Medicine · 14
PDF
A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study
2014 · Dave Singh, Helena Pujol, et al. · BMC Pulmonary Medicine · 14
PDF
Abediterol (LAS100977), a novel long-acting β2-agonist: Efficacy, safety and tolerability in persistent asthma
2014 · J. Beier, R. Fuhr, et al. · Respiratory Medicine · 14
PDF
Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II , randomized, 7‐day, crossover study
2017 · Jutta Beier, Rainard Fuhr, et al. · Pharmacology Research & Perspectives · 10
PDF
Single Doses Of LAS100977, A Novel Long Acting ²2-agonist, Show High Activity And Long Duration In Healthy Subjects
2010 · Wolfgang Timmer, Èric Massana, et al. · American Journal of Respiratory and Critical Care Medicine · 10
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)
2025 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology · 8
Efficacy And Safety Of Single Inhaled Doses Of LAS100977, A Novel Long Acting ²2-agonist In Patients With Persistent Asthma
2010 · Jutta Beier, Rainard Fuhr, et al. · American Journal of Respiratory and Critical Care Medicine · 7
No Sex-related Pharmacokinetic and Pharmacodynamic Differences of Captopril
1997 · E. MASSANA, M.J. BARBANOJ, et al. · Pharmacological Research · 7
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
2025 · Matthias Augustin, Anthony Bewley, et al. · BMJ Open · 5
Pharmakokinetik, Sicherheit und Aktivität von Formoterol verabreicht über den Genuair Inhalator® mit und ohne Aclidinium-Bromid
2011 · H Magnussen, H Watz, et al. · Pneumologie · 5
Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
2014 · Jutta Beier, Rainard Fuhr, et al. · European Respiratory Journal · 4
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
2025 · Ulrich Mrowietz, Rachel Sommer, et al. · Psoriasis Targets and Therapy · 3
PDF
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)
2024 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology · 2
El ensayo clínico: protocolos de investigación, cálculo del tamaño de la muestra, información de resultados y consideraciones éticas (II parte)
1996 · Campos D Saenz, Ignasi Gich, et al. · Revista Costarricense de Ciencias Médicas · 2
52653 Real-world effectiveness, quality of life, and treatment satisfaction with tildrakizumab in patients with moderate-to-severe psoriasis: 28-week interim data of the phase IV POSITIVE study
2024 · Matthias Augustin, Rachel Sommer, et al. · Journal of the American Academy of Dermatology · 1
PDF
75192 Beyond skin clearance: Tildrakizumab improves high burdensome symptoms and psychological well-being in moderate-to-severe psoriasis patients – 2-year POSITIVE study results
2026 · Ulrich Mrowietz, Rachel Sommer, et al. · Journal of the American Academy of Dermatology
71092 Sustained effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study
2026 · Matthias Augustin, Rachel Sommer, et al. · Journal of the American Academy of Dermatology
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
2026 · Ulrich Mrowietz, Rachel Sommer, et al. · Psoriasis Targets and Therapy
PDF
62852 A holistic approach to patients with moderate-to-severe plaque psoriasis in a real-world setting: improvements with tildrakizumab beyond the skin lesions
2025 · Ulrich Mrowietz, Rachel Sommer, et al. · Journal of the American Academy of Dermatology
P104 Lebrikizumab improves quality of life in patients with moderate-to-severe atopic dermatitis inadequately controlled or ineligible for ciclosporin (ADvantage study)
2025 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology
PDF
P102 Raising the bar of efficacy in atopic dermatitis: lebrikizumab provides deep clinical and itch responses up to 16 weeks (ADvantage study)
2025 · Richard B Warren, Marjolein de Bruin-Weller, et al. · British Journal of Dermatology
PDF
Les patients atteints de psoriasis modéré à sévère traités par tildrakizumab rapportent un indice de bien-être équivalent à celui de la population générale sans maladie chronique
2024 · R. Sommer, M. Augustin, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Works count: 37
Citation count: 346
H-index: 8
I10-index: 8
Year
Topic
Type